Advertisement

Expert’s comment concerning Grand Rounds case entitled “Retroperitoneal haematoma in a postoperative ALIF patient taking rivaroxaban for atrial fibrillation” by Deekonda P, Stokes OM, Chan D (Eur Spine J [2016]: DOI 10.1007/s00586-016-4822-8)

  • Anthony Todd
Expert's Comment

This is a clear and well-constructed case report describing retroperitoneal haemorrhage in a 72-year-old man taking the oral anticoagulant, rivaroxaban, shortly after spinal surgery and a related literature review [1]. The authors describe the patient’s presentation and bleeding management as well as summarise some key issues around NOACs and surgery.

Rivaroxaban directly inhibits factor Xa, a vital enzyme in the clotting pathway. Its onset of action is rapid, peaking at 2–4 h after ingestion, and with an elimination half-life of around 12 h or less, anticoagulation has generally worn off within 48–72 h of last exposure [2]. I will make some specific comments on the peri-operative management of rivaroxaban and the emergency management of major haemorrhage associated with NOACs.

Emergency management

The authors rightly point out that specific reversal agents are needed, with none available at the time of their report. It is common for guidelines on managing NOAC-associated bleeding to...

Notes

Compliance with ethical standards

Conflict of interest

The author declares that he has no conflict of interest.

References

  1. 1.
    Deekonda P, Stokes OM, Chan D (2016) Retroperitoneal haematoma in a postoperative ALIF patient taking rivaroxaban for atrial fibrillation. Eur Spine J.  https://doi.org/10.1007/s00586-016-4822-8 CrossRefPubMedGoogle Scholar
  2. 2.
    European Medicines Agency (2018) Xarelto 2.5 mg, Summary of product characteristics https://www.medicines.org.uk/emc/product/3410/smpc. Accessed 20 Nov 2018
  3. 3.
    PHARMAC, Best Practice Advocacy Centre New Zealand, New Zealand Government (2017) Guidelines for management of bleeding with dabigatran or rivaroxaban: for possible use in local management protocols. https://bpac.org.nz/2018/docs/dabigatran-rivaroxaban-bleeding-management.pdf. Accessed 20 Nov 2018
  4. 4.
    Makris M, Van Veen JJ, Tait CR, Mumford AD, Laffan M (2013) Guideline on the management of bleeding in patients on antithrombotic agents. Br J Haematol 160(1):35–46CrossRefGoogle Scholar
  5. 5.
    Clinical Excellence Commission (2017) Non-vitamin K antagonist oral anticoagulant (NOAC) Guidelines, Updated July 2017. Sydney, AustraliaGoogle Scholar
  6. 6.
    Sarode R, Milling TJ Jr, Refaai MA et al (2013) Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation 128:1234–1243CrossRefGoogle Scholar
  7. 7.
    Levy JH, Moore KT, Neal MD, Schneider D, Marcsisin VS, Ariyawansa J, Weitz JJ (2018) Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers. Thromb Haemost 16(1):54–64CrossRefGoogle Scholar
  8. 8.
    Sørensen B, Spahn DR, Innerhofer P, Spannagl M, Rossaint R (2011) Clinical review: prothrombin complex concentrates—evaluation of safety and thrombogenicity. Crit Care 15(1):201–209CrossRefGoogle Scholar
  9. 9.
    Connolly SJ, Milling TJ Jr, Eikelboom JW et al (2016) Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 375(12):1131–1141.  https://doi.org/10.1056/NEJMoa1607887 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Radcliff KE, Ong A, Parvizi J, Post Z, Orozco F (2014) Rivaroxaban-induced epidural hematoma and cauda equina syndrome after total knee arthroplasty: a case report. Orthop Surg 2014(6):69–71.  https://doi.org/10.1111/os.12085 CrossRefGoogle Scholar
  11. 11.
    Zaarour M, Hassan S, Thumallapally N, Dai Q (2015) Rivaroxaban-induced nontraumatic spinal subdural hematoma: an uncommon yet life-threatening complication. Case Rep Hematol.  https://doi.org/10.1155/2015/275380 CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Pollack CV, Reilly PA, Eikelboom J et al (2015) Idarucizumab for dabigatran reversal. N Engl J Med 373:511–520.  https://doi.org/10.1056/NEJMoa1502000 CrossRefPubMedGoogle Scholar
  13. 13.
    The EINSTEIN-PE Investigators (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366:1287–1297.  https://doi.org/10.1056/NEJMoa1113572 CrossRefGoogle Scholar
  14. 14.
    United States Food and Drug Administration (2016) Xarelto medication guide https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202439s017lbl.pdf. Accessed 18 Nov 2018
  15. 15.
    Hylek EM, Held C, Alexander JH et al (2014) Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE trial (Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation): predictors, characteristics, and clinical outcomes. J Am Coll Cardiol 63(20):2148–2150.  https://doi.org/10.1016/j.jacc.2014.02.549 CrossRefGoogle Scholar
  16. 16.
    Saxena N, Parajuli S (2016) Spontaneous perinephric haematoma with newer oral anticoagulation in kidney transplant recipient. J Nephrol Renal Ther 2(1):1–2.  https://doi.org/10.24966/NRT-7313/100002 CrossRefGoogle Scholar
  17. 17.
    Douketis JD, Spyropoulos AC, Spencer FA et al (2012) Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of chest physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e326S–e350S.  https://doi.org/10.1378/chest.11-2298 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Sherwood MW, Douketis JD, Patel MR et al (2014) Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation (ROCKET AF). Circulation 129(18):1850–1859CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of HaematologyThe Royal Devon and Exeter HospitalDevonUK

Personalised recommendations